Physician profile
Tong Sun
NPI 1629161336
$4,410.68
in general payments reported to CMS, 2019-2025
23 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $239 · 2021: $606 · 2022: $1,047 · 2023: $720 · 2024: $812 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.93 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $891.53 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $623.50 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Gastroklenz, INC. Dba Cloudcath | $400.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $393.64 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $249.18 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $220.98 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $217.05 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $216.20 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $211.05 | 2019-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.80 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $132.54 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $128.84 | 2021-2024 | Jesduvroq |
| Mallinckrodt Hospital Products INC. | $118.68 | 2020-2022 | |
| Novo Nordisk INC | $86.81 | 2023-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $70.58 | 2021-2023 | Krystexxa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $60.61 | 2024-2025 | Ibsrela |
| Kyowa Kirin, INC. | $47.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $42.56 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $37.85 | 2019-2022 | |
| Ascendis Pharma Endocrinology INC | $27.96 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $24.37 | 2025 | |
| Janssen Pharmaceuticals, INC | $24.12 | 2020 | |
| Lilly USA, LLC | $19.85 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tong Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.